Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sergey Petrosian

Dermatology Brooklyn, NY Doctor of Osteopathy

NPI 1538520192 CMS profile 8803276

76 7Th Ave, Brooklyn, NY 11217

Open in the dashboard

General payments

$24,322

453 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sergey Petrosian of Brooklyn, NY is reported in the CMS Open Payments database as having received $24,322 across 453 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,453 93
2024 General $6,527 134
2023 General $1,938 97
2022 General $1,277 62
2021 General $1,025 62
2020 General $102 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sergey Petrosian
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Sergey Petrosian were reported at $13,453. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Sergey Petrosian Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $102 $235 $81–$756 $114
2021 $1,025 $377 $108–$1,108 $132
2022 $1,277 $514 $143–$1,391 $149
2023 $1,938 $607 $159–$1,674 $160
2024 $6,527 $751 $204–$1,903 $164
2025 $13,453 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Organon LLC $11,743 17 payments
  2. Dermavant Sciences, Inc. $4,998 66 payments
  3. AbbVie, Inc. $2,443 122 payments
  4. Janssen Biotech, Inc. $1,069 46 payments
  5. Sun Pharmaceutical Industries Inc. $658 33 payments
  6. Lilly USA, LLC $572 25 payments
  7. Incyte Corporation $368 15 payments
  8. Regeneron Healthcare Solutions, Inc. $298 11 payments
  9. Galderma Laboratories, L.P. $262 25 payments
  10. Pfizer Inc. $250 10 payments
  11. Other $1,661 83 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $11,130 2 payments
  2. Food and Beverage $9,708 444 payments
  3. Travel and Lodging $3,338 5 payments
  4. Education $145 2 payments
Products named General payments · program years 2020–2025
  1. VTAMA $16,722 82 payments
  2. SKYRIZI $1,085 52 payments
  3. TREMFYA $1,069 46 payments
  4. RINVOQ $1,061 54 payments
  5. TALTZ $531 23 payments
  6. ILUMYA $463 24 payments
  7. OPZELURA $368 15 payments
  8. HUMIRA $280 14 payments
  9. DUPIXENT Inflammation And Immunology $267 10 payments
  10. DUPIXENT Immunology $236 8 payments
  11. Other $3,238 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

462

Median for Dermatology: 534

Drug cost

$66,802

Median for Dermatology: $67,151

Branded share of claims

5.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $52,800
Clobetasol Propionate Generic 61 $3,175
Tacrolimus Generic 12 $2,609
Ketoconazole Generic 114 $1,901
Azelaic Acid Generic 16 $1,622
Fluocinonide Generic 35 $1,357
Clindamycin Phosphate Generic 12 $641
Nystatin Generic 26 $532
Triamcinolone Acetonide Generic 60 $505
Ciclopirox Generic 14 $353

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$113,587

Of which drugs: $4,381

Medicare patients

316

Average age 75

Services billed

4,851

167 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 49%
Diabetes 31%
Ischemic heart disease 27%
Depression 19%
Osteoporosis 17%
Cancer 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 79 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $4,290
$4,290 — —
TREMFYA
  • Janssen Biotech, Inc. $977
$977 — —
SKYRIZI
  • AbbVie, Inc. $198
$198 — —
TALTZ
  • Lilly USA, LLC $158
$158 — —
RINVOQ
  • AbbVie, Inc. $158
$158 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

453 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record